



Supplemental Figure 1




Supplemental Figure 1. Identification of *TbKIN-C* gene. (A). Strategy for identification of cytokinesis defect genes by genomic RNAi screen in the procyclic form of *T. brucei*. (B). Phenotypes of the *TbKIN-C* mutant identified by RNAi screen. Bars: 10 μ m. (C). Schematic representation of the structure of *TbKIN-C*. Alignment of the conserved motifs in the motor domain of *TbKIN-C* with that of trypanosome *TbKIN-A*, and human *Kin-5* and *Kin-6* kinesins is presented. Black arrowhead pointed to the conserved lysine residue that is essential for ATP binding and is mutated to alanine in *TbKIN-C* (K196A) for *in vitro* ATPase assays. (D). Location of the coiled-coil motifs at the C-terminus of *TbKIN-C* as predicted by the COILS program.

Supplemental Figure 2



Supplemental Figure 2. Morphology of TbKIN-C RNAi cells. Cells were fixed with paraformaldehyde and stained with DAPI for nuclear and kinetoplast DNA. The arrows pointed to detached flagellum. Bars: 2 μ m.

Supplemental Figure 3



Supplemental Figure 3. RNAi of TbKIN-C does not inhibit mitotic progression in the procyclic form of *T. brucei*. (A). Effect of TbKIN-C RNAi on mitotic progression in the procyclic form of *T. brucei*. Control and TbKIN-C RNAi cells were fixed and stained with anti-H3K76me2 antibody, a mitotic marker in trypanosomes. Bars: 2 μ m. (B). Percentage of mitotic cells in control and TbKIN-C RNAi cells as determined by anti-H3K76me2 antibody staining. Data are presented as the mean percent \pm S.D. of \sim 200 cells counted from three independent experiments.